However, a recent individual meta-analysis of 2310 patients showed that HER2-low-positive BC had a significant favorable survival than HER2-0 BC(OS: p=0.0016), and similar results were detected among HR (−) tumors (OS: p=0.016), but not for HR (+) positive BC (p = 0.13) [15]. Here, ERBB2 is linked to breast cancer.